NDA 215814 · Rigel Pharms
Rezlidhia
Olutasidenib · Oral
NovelOrphanCDER novel approval, Dec 1, 2022: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
Last checked: Nov 20, 2026Latest source record: Dec 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 1, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
0 Phase 3, 12 recruiting
FAERS reports
289
164 serious, 45 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain. If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution [see Warnings and Precautions ( 5.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. If differentiation syndrome is suspected, withhold REZLIDHIA and initiate corticosteroids and hemodynamic monitoring until symptom resolution. ( 5.1 )
What it is approved for
From the label in effect Nov 5, 2025.
Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. ( 1 )
Mechanism: Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of olutasidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of olutasidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations in patients with AML are R132H and R132C substitutions....
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 1, 2022 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelMedication Guide
1 products under this application
- REZLIDHIA · OLUTASIDENIB 150MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olutasidenib" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
Forma Therapeutics, Inc.Industry
NCT02719574 · 336 participants · Start Apr 30, 2016 · Primary completion Dec 28, 2023
Drug: FT-2102 (olutasidenib); Azacitidine and 1 more · For: Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Sites: Los Angeles, California; Sacramento, California; New Haven, Connecticut · 60 sites in all
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04603001 · 260 participants (planned) · Start Nov 19, 2020 · Primary completion Jul 3, 2023
Drug: LY3410738; Venetoclax and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML) and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 37 sites in all
- Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)Pivotal-lookingNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07153497 · 132 participants (planned) · Start Nov 27, 2026 · Primary completion Apr 26, 2030
Drug: Decitabine and Cedazuridine; Olutasidenib and 1 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome
- A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 MutationCompleted
Forma Therapeutics, Inc.Industry
NCT03684811 · 93 participants · Start Nov 1, 2018 · Primary completion May 24, 2021
Drug: FT-2102; Azacitidine and 2 more · For: Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma and 2 more
Sites: Gilbert, Arizona; Aurora, Colorado; Miami, Florida · 26 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06445959 · 78 participants (planned) · Start Aug 29, 2024 · Primary completion Jun 30, 2027
Drug: Olutasidenib; Venetoclax and 2 more · For: Mutant IDH1 Inhibitor Olutasidenib
Sites: Miami, Florida; Westwood, Kansas; Boston, Massachusetts · 5 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07032727 · 68 participants (planned) · Start Sep 12, 2025 · Primary completion Jun 1, 2027
Drug: Olutasidenib; Cladribine (CLAD) and 4 more · For: Targeted Therapy; IDH1-Mutated Malignancies; Mutations
Sites: Miami, Florida; Houston, Texas
Rigel PharmaceuticalsIndustry
NCT06161974 · 60 participants (planned) · Start Feb 1, 2025 · Primary completion Jun 2029
Drug: Olutasidenib + TMZ · For: High Grade Glioma; Astrocytoma; Astrocytoma, Grade III and 16 more
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Miami, Florida · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use75
- hospitalisation43
- death40
- fatigue27
- nausea27
- product dose omission issue25
- product prescribing issue23
- constipation17
- transfusion13
- pneumonia11
- drug ineffective10
- dyspnoea10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 41 |
| 2024 | 91 |
| 2025 | 111 |
| 2026 | 46 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rezlidhia (Olutasidenib)
2024 spending
$15.5M
Beneficiaries
134
505 claims
Per beneficiary
$115,549
$530.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $7,155,400 |
| 2024 | $15,483,548 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Cortes J, Curti A, Fenaux P, et al. · J Hematol Oncol 2025 · Clinical Trial, Phase II, Multicenter Study
- Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Cortes JE, Roboz GJ, Baer MR, et al. · J Hematol Oncol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.
Cortes JE, Yang J, Roboz GJ, et al. · Blood Adv 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, et al. · Neuro Oncol 2023 · Multicenter Study, Clinical Trial, Phase I
- Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL, Groisberg R, Blay JY, et al. · Nat Commun 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, et al. · Lancet Haematol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: Rigel Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.